Form 6K Alterity Therapeutics Ltd For: 28 July
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alterity Therapeutics Ltd (ATHE)
Alterity Therapeutics Ltd stock price live, this page displays NASDAQ ATHE stock exchange data. View the ATHE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Alterity Therapeutics Ltd real time stock price chart below.
What Is the Alterity Therapeutics Ltd Stock Price Today?
The Alterity Therapeutics Ltd stock price today is 5.1500.
What Is the Stock Symbol for Alterity Therapeutics Ltd?
The stock symbol for Alterity Therapeutics Ltd is ""ATHE.""
What Stock Exchange Does Alterity Therapeutics Ltd Trade On?
Alterity Therapeutics Ltd is listed and trades on the NASDAQ stock exchange.
Is Alterity Therapeutics Ltd a Good Stock to Buy?
Determining whether Alterity Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATHE quote. (ISIN: US02155X2053)
What Is the Alterity Therapeutics Ltd Stock Price Today?
The Alterity Therapeutics Ltd stock price today is 5.1500.
What Is the Stock Symbol for Alterity Therapeutics Ltd?
The stock symbol for Alterity Therapeutics Ltd is ""ATHE.""
What Stock Exchange Does Alterity Therapeutics Ltd Trade On?
Alterity Therapeutics Ltd is listed and trades on the NASDAQ stock exchange.
Is Alterity Therapeutics Ltd a Good Stock to Buy?
Determining whether Alterity Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATHE quote. (ISIN: US02155X2053)
5.1500
-0.2500(-4.63%)
Closed·
After Hours
5.15000.0000(0.00%)
·
Fair Value
An estimate of a Alterity Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.1100
5.4200
52 wk Range
1.0010
7.0000
ATHE Scorecard
Full Analysis
Analysts do not anticipate the company will be profitable this year
ATHE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Alterity Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.11005.4200
52 wk Range
1.00107.0000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ATHE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Alterity Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
11.0000
Upside
+113.59%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High return over the last year
- Alterity Therapeutics highlighted at MSA Congress
- Investing.com
- Form 6K Alterity Therapeutics Ltd For: 24 July
- Investing.com
- Form 6K Alterity Therapeutics Ltd For: 28 July
- Investing.com
- Form 6K Alterity Therapeutics Ltd For: 24 July
- Investing.com
- Form 6K Alterity Therapeutics Ltd For: 23 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
Alterity Therapeutics Ltd Company Profile
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Compare ATHE to Peers and Sector
Metrics to compare | ATHE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATHEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.5x | −4.9x | −0.5x | |
PEG Ratio | −0.32 | −0.02 | 0.00 | |
Price/Book | 16.6x | 3.0x | 2.6x | |
Price / LTM Sales | 34.6x | 13.6x | 3.3x | |
Upside (Analyst Target) | 103.7% | 276.9% | 42.8% | |
Fair Value Upside | Unlock | 10.7% | 6.5% | Unlock |
Analyst Ratings
2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 11.0000
(+113.59% Upside)
Earnings
Latest Release
Feb 28, 2025
EPS / Forecast
-- / -0.11
Revenue / Forecast
1.61M / --
People Also Watch
FAQ
What Stock Exchange Does Alterity Therapeutics Trade On?
Alterity Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Alterity Therapeutics?
The stock symbol for Alterity Therapeutics is "ATHE."
What Is the Alterity Therapeutics Market Cap?
As of today, Alterity Therapeutics market cap is 83.63M.
What Is Alterity Therapeutics's Earnings Per Share (TTM)?
The Alterity Therapeutics EPS (TTM) is -0.00.
From a Technical Analysis Perspective, Is ATHE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Alterity Therapeutics Stock Split?
Alterity Therapeutics has split 2 times.
How Many Employees Does Alterity Therapeutics Have?
Alterity Therapeutics has 10 employees.
What is the current trading status of Alterity Therapeutics (ATHE)?
As of 06 Aug 2025, Alterity Therapeutics (ATHE) is trading at a price of 5.15, with a previous close of 5.40. The stock has fluctuated within a day range of 5.11 to 5.42, while its 52-week range spans from 1.00 to 7.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.